Early access to innovative medicines (EAM) is a crucial mechanism in the healthcare sector, particularly in France, allowing patients to quickly benefit from new treatments even before their official marketing authorization.
The regulations surrounding the products that can be listed and sold in pharmacies are both strict and dynamic, evolving in line with scientific advances, public health needs, and European directives.
France is currently facing a major concern: a shortage of medicines that could directly affect the health of its population. The shortage particularly affects an essential antibiotic, amoxicillin, which is particularly prescribed for children.
The recent wave of drug shortages that has rocked France has highlighted the need to put in place effective measures to ensure a reliable supply of essential medicines.
We are delighted to present an exclusive interview with our Director of Operations at Pharmafield, who spoke about the future of the post-Covid medical visit.